1. Serine phosphorylation facilitates protein degradation by the human mitochondrial ClpXP protease.
- Author
-
Feng Y, Goncalves MM, Jitkova Y, Keszei AFA, Yan Y, Sarathy C, St-Germain J, Kenney TMG, Tcheng M, Trudel V, Mancini RS, Upadhyay R, Hurren R, Gronda M, Schultz M, Soriano K, Lees K, Pomroy NC, Currie SQW, Privé GG, Reed MA, Yudin AK, Penn LZ, Arrowsmith CH, Raught B, Mazhab-Jafari MT, Vahidi S, and Schimmer AD
- Subjects
- Humans, Phosphorylation, Mitochondrial Proteins metabolism, Mitochondrial Proteins genetics, Substrate Specificity, ATPases Associated with Diverse Cellular Activities metabolism, ATPases Associated with Diverse Cellular Activities genetics, Endopeptidase Clp metabolism, Endopeptidase Clp genetics, Proteolysis, Serine metabolism, Mitochondria metabolism
- Abstract
ClpXP is a two-component mitochondrial matrix protease. The caseinolytic mitochondrial matrix peptidase chaperone subunit X (ClpX) recognizes and translocates protein substrates into the degradation chamber of the caseinolytic protease P (ClpP) for proteolysis. ClpXP degrades damaged respiratory chain proteins and is necessary for cancer cell survival. Despite the critical role of ClpXP in mitochondrial protein quality control, the specific degrons, or modifications that tag substrate proteins for degradation by human ClpXP, are still unknown. We demonstrated that phosphorylated serine (pSer) targets substrates to ClpX and facilitates their degradation by ClpXP in biochemical assays. In contrast, ClpP hyperactivated by the small-molecule drug ONC201 lost the preference for phosphorylated substrates. Hydrogen deuterium exchange mass spectrometry combined with biochemical assays showed that pSer binds the RKL loop of ClpX. ClpX variants with substitutions in the RKL loop failed to recognize phosphorylated substrates. In intact cells, ClpXP also preferentially degraded substrates with pSer. Moreover, ClpX substrates with the pSer were selectively found in aggregated mitochondrial proteins. Our work uncovers a mechanism for substrate recognition by ClpXP, with implications for targeting acute myeloid leukemia and other disorders involving ClpXP dysfunction., Competing Interests: Competing interests statement:A.D.S. has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Astra-Zeneca, BMS, and Novartis, Pharmaceuticals. A.D.S. is on the medical and scientific board of the Leukemia and Lymphoma Society of Canada. S.V. is the founder and Chief Scientific Officer of OncoMathica Inc. A.D.S. is named on a patent application for the use of DNT cells to treat AML.
- Published
- 2025
- Full Text
- View/download PDF